Breaking — the
cycle — of — infection
Developing a proprietary therapeutic platform designed to provide durable protection against persistent and latent viral diseases through a single injection
Treatment suppresses.
The virus persists.
Current therapies can suppress persistent viral infections, but treatment often continues for years or decades. Without a functional cure, many patients face lifelong treatment for a virus that will rebound if treatment stops.
HBV Global Disease Burden
240M
people living with
chronic HBV
1.1M
HBV-related deaths
annually
CMV Transplant Risk
50-70%
CMV reactivation risk after
bone marrow transplant*
Perpetuu Biosciences
1
injection designed for sustained antibody expression
*Kharfan-Dabaja MA, et al. Vaccines. 2013;1:398–414.
Perpetuu is breaking the cycle.
Solving persistent viral disease requires a different approach. Perpetuu is advancing an AAV-delivered antibody therapy platform designed to provide sustained in vivo expression of neutralizing antibodies following a single administration.
Explore our practical path toward durable functional cures for chronic disease.
Our platform
A flexible antibody platform for persistent viral disease
Perpetuu is advancing a proprietary AAV-delivered antibody platform designed to provide durable expression of therapeutic antibodies following a single administration. By maintaining antibody levels over time, the platform is designed to continuously block viral spread and reservoir replenishment.
Our pipeline
Advancing co-lead programs in CMV and chronic hepatitis B
Perpetuu is applying its proprietary platform to two co-lead programs: CMVZ01, designed to provide durable CMV prophylaxis in high-risk transplant patients, and HBVZ10, designed to support a functional cure strategy for chronic hepatitis B.
Together, the programs provide complementary opportunities to demonstrate the potential of sustained in vivo antibody expression across persistent viral diseases.
HBVZ10, our co-lead chronic hepatitis B candidate, has demonstrated durable antibody expression and potent antiviral activity in humanized-liver mouse models, both as monotherapy and in combination with entecavir.
Our capabilities
Why Perpetuu is different
1 — Single administration
Our AAV-delivered antibody technology is designed to provide sustained therapeutic antibody expression following a single administration, rather than requiring repeated antibody dosing.